1. Biologics such as dupilumab, tralokinumab, lebrikizumab, and nemolizumab improved symptoms and quality of life in patients with atopic dermatitis.
2. Dupilumab maintained high treatment persistence, with 80% to 90% of adults and children remaining on therapy over three years.
3. Nemolizumab provided rapid itch relief, with improvements observed as early as the first week of treatment.
4. Safety findings were consistent with clinical trials, although ocular surface disease occurred more often in real-world settings.
5. Biologics also improved skin barrier function and reduced inflammatory biomarkers associated with atopic dermatitis.
6. Extending dosing intervals helped maintain disease control and lowered overall treatment costs.

Source: Allergy